Please login to the form below

Not currently logged in
Email:
Password:

BMJ: 'Lilly acted properly'

The British Medical Journal has officially apologised to Eli Lilly & Co for accusing it of hiding side effect data relating to antidepressant, Prozac.

The British Medical Journal (BMJ) has apologised officially to US pharmaceutical company Eli Lilly & Co and has withdrawn certain claims it made over the questionable disclosure of side effect data relating to antidepressant Prozac.

The journal, one of the country's most esteemed publications, alleged in an article published in early January that documentary evidence of what were described as ìtroubling side effectsî linked to Lilly's top-selling antidepressant, had ìgone missingî during a product liability lawsuit in 1994.

The evidence in question was later submitted to the BMJ by a source, who remains anonymous, and the journal in turn submitted it to America's Food and Drug Administration in what some saw as rather atypical behaviour for a publication of its type.

Following a complaint by Lilly, which said it was ìdisturbedî as the article in January ìinaccurately reported about Prozac and made negative references regarding [the] company's conductî, the BMJ conducted a deeper investigation and then retracted the claims.

ìAs a result of a detailed investigation, it is clear that these documents did not go missing. The BMJ is happy to set the record straight and to apologise to Eli Lilly,î it stated. Lilly accepted its apology.

However, despite acting editor Kamran Abbasi's proclamation that ìthe BMJ did not intend to suggest that Eli Lilly caused these documents to go missingî, he remains adamant that other parts of the article are accurate; notably, claims that Lilly was aware of Prozac's ìtroubling side effectsî in the 1980s, and hence the question over whether the alleged ìmissingî documents were submitted to the FDA at the appropriate time is still yet to be answered.

As part of the SSRI (selective serotonin reuptake inhibitor) class of antidepressant medications, Prozac bore a good deal of scrutiny in 2004 when a furore sprang up based on potential links to suicidal behaviour in juvenile patients on withdrawal of medication.

All companies marketing SSRIs were obliged by regulators to make immediate label changes, however GlaxoSmithKline, which makes Seroxat, seemed to bear the brunt of the pressure. Prozac is currently the only such drug approved by the FDA for treating children.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics